Navigation Links
K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P
Date:10/13/2011

ST. LOUIS, Oct. 13, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (the "Company") (NYSE:  KVa/KVb) appreciates the decision of the American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM) to issue an information update and ensure that healthcare providers, patients, and the payer community have the facts regarding FDA-approved Makena™.  The information update from ACOG and SMFM confirms that FDA-approved Makena and unapproved compounded 17P formulations are not identical.  The update also emphasizes the importance of honoring the clinical decisions of healthcare professionals, and makes clear that previous ACOG and SMFM statements should not be used by payers to deny coverage for Makena.  

Healthcare providers understand that evidence-based medicine is the foundation of clinical practice.  The ACOG and SMFM update acknowledges that evidence from the NICHD MFMU Network study (Meis, et al.) supporting the use of hydroxyprogesterone caproate (17P) was based on drug manufactured under FDA's Good Manufacturing Practices (GMP) conditions, and not on drug made using compounding processes or obtained from compounding pharmacies.  The drug used in the NICHD study is available today as FDA-approved Makena.  

Access to FDA-approved Makena for clinically-indicated patients is an important public health priority.  Certain payer coverage policies have been influenced by an incorrect belief that unapproved compounded 17P formulations are the same as Makena.  These policies should be modified to ensure that clinically-indicated patients have unencumbered access to FDA-approved Makena, consistent with their healthcare professional's medical judgment.  

As part of our commitment to patients, we have made substantial efforts to help ensure affordable access to therapy, and patient co-pays for Makena are averaging approximately $12 per injection.  '/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
2. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
3. Amylin Pharmaceuticals to Webcast Third Quarter Results
4. Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer
5. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
6. Unity Management Group Receives Large Purchase Order for their AIM Instrumentation Package From Barr Laboratories, Subdivision of TEVA Pharmaceuticals (NASDAQ: TEVA)
7. Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011
8. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
9. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
10. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
11. Huifeng Bio-Pharmaceutical Technology, Inc. to Attend 2011 CPhI Frankfurt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... ATLANTA , Sept. 30, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... received a $25 million advance from Hercules Technology Growth ... payment is the second and final advance under the ... United Kingdom , Alimera Sciences Limited, ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... JERUSALEM, October 20 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB; ... today that its poster entitled "A novel GLP-1,analog delivered ... been accepted for presentation at the Diabetes Technology,Society,s Ninth ... , "The selection of Oramed ...
... Oct. 20 Aethlon Medical, Inc. (OTC Bulletin Board: ... Aethlon Hemopurifier® is effective in capturing the current pandemic ... is the first-in-class medical device able to selectively remove ... During invitro studies, the Hemopurifier® removed 68% ...
Cached Medicine Technology:Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA) 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 3
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... 30, 2014 Fat Burning Kitchen , ... best-selling author Mike Geary that is helping people learn the ... into a fat-burning machine in less than 24 hours has ... , “In our culture that is becoming so obsessed ... decipher what is really fact and fiction when it comes ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Two revolutionary procedures ... treatment of gum disease a far less painful ... past. , “If you’ve ever felt electric shock waves surge ... sip a cold beverage, it’s possible you already know the ... who is a general dentist in West Palm Beach, and ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... PHILADELPHIA, May 15 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... the 7th Annual Yoga Unites(R) for Living Beyond Breast Cancer ... May 17, from 8:00 a.m. to 12:00 p.m. on the ...
... Paul Capital Healthcare today announced that New York-based partner, ... forms of financing at the 2009 BIO International Convention. ... non-dilutive financing options that can meet the needs of ... and Other Non-traditional Forms of Financing," is scheduled for ...
... PTN ) announced today results for its third quarter ... million, or $0.00 per basic and diluted share, for the quarter ... million, or $0.06 per basic and diluted share, for the same ... 31, 2009 were $5.2 million, compared to $0.7 million for the ...
... Researchers at Intermountain Medical Center in Salt Lake City ... atrial fibrillation, a fairly common heart rhythm disorder, and ... , In a study presented Friday, May 15, at ... Heart Rhythm Society in Boston, researchers unveiled findings from ...
... (NYSE Amex:, SVA ), a leading developer and provider of vaccines ... March 31, 2009. , , Recent Highlights, ... sole provider of, approximately $12.8 million ... inactivated hepatitis A vaccine, Healive, to China,s Ministry of Public, ...
... - U.S. and international thought leaders featured -SAN FRANCISCO, ... trusted resource for clinical trial management systems, this week ... institutions and industry partners at its annual meeting in ... to discuss a variety of initiatives and to hear ...
Cached Medicine News:Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6Health News:Study makes first connection between heart disorder and Alzheimer's disease 2Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 2Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 3Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 4Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 5Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 6Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 7Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 8Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 9Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 10Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 11Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 12Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 13Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 2Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 3
...
...
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
Medicine Products: